Literature DB >> 15494280

Endoscopic and surgical management of leakage and mediastinitis after esophageal surgery.

H Messmann1, Werner Schmidbaur, Jürgen Jäckle, Alois Fürst, I Iesalnieks.   

Abstract

Due to the specialisation of esophageal surgery a significant reduction of post-surgical mortality was possible during the last few decades. Nevertheless a high complication rate of about 30% remains even in the hands of experienced surgeons. Anastomotic leakage has an incidence between 5 and 30% leading to serious postoperative morbidity. With a broad range of conservative and endoscopic therapeutic methods there is encouraging progress in shortening the time to closure of the leakage and reducing the risk of severe systemic complications such as sepsis or malnutrition. If conservative therapy fails, re-surgery remains as an ultima-ratio option.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494280     DOI: 10.1016/j.bpg.2004.05.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  3 in total

Review 1.  Endoscopic Management of Benign Esophageal Ruptures and Leaks.

Authors:  Milena Di Leo; Roberta Maselli; Elisa Chiara Ferrara; Laura Poliani; Sameer Al Awadhi; Alessandro Repici
Journal:  Curr Treat Options Gastroenterol       Date:  2017-06

2.  Non-malignant respiratory tract fistula from the oesophagus. A lethal condition for which novel therapeutic options are emerging.

Authors:  Peter Elbe; Mats Lindblad; Jon Tsai; Jan-Erik Juto; Gert Henriksson; Thorhallur Agustsson; Lars Lundell; Magnus Nilsson
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-11-25

3.  Endoscopic vacuum therapy versus stent treatment of esophageal anastomotic leaks (ESOLEAK): study protocol for a prospective randomized phase 2 trial.

Authors:  Michael Tachezy; Seung-Hun Chon; Isabel Rieck; Marcus Kantowski; Hildegard Christ; Karl Karstens; Florian Gebauer; Tobias Goeser; Thomas Rösch; Jakob R Izbicki; Christiane J Bruns
Journal:  Trials       Date:  2021-06-02       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.